Inactive Instrument

News Wound Management Technologies Inc Other OTC

Equities

US98211X1063

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sanara MedTech Inc. Announces $55 Million Debt Facility	Apr. 18	AQ
Sanara Medtech Inc. Announces $55 Million Debt Facility	Apr. 18	CI
Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer	Apr. 05	MT
Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer	Apr. 05	AQ
Sanara MedTech Inc. Announces Executive Changes, Effective April 15, 2024	Apr. 05	CI
Cantor Fitzgerald Cuts Price Target on Sanara MedTech to $44 From $49, Maintains Overweight Rating	Mar. 27	MT
Transcript : Sanara MedTech Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Earnings Flash (SMTI) SANARA MEDTECH Posts Q4 Revenue $17.7M, vs. Street Est of $16.5M	Mar. 25	MT
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results	Mar. 25	AQ
Sanara MedTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates	Mar. 13	AQ
Sanara MedTech Reports Higher Preliminary Q4 Revenue	Feb. 22	MT
Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023	Feb. 22	AQ
Sanara MedTech Inc. Announces Unaudited Preliminary Net Revenue Results for the Fourth Quarter and Full-Year 2023	Feb. 22	CI
Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides	Jan. 03	AQ
Sanara MedTech Secures Exclusive Licensing Deal with Tufts University for 18 Collagen Peptides	Jan. 03	MT
Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing	Nov. 30	AQ
Cantor Fitzgerald Adjusts Price Target on Sanara MedTech to $49 From $59, Maintains Overweight Rating	Nov. 15	MT
Transcript : Sanara MedTech Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Sanara MedTech Q3 Loss Narrows, Revenue Rises; Shares Fall After Hours	Nov. 13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Wound Management Technologies Inc Other OTC

Equities

US98211X1063

Summary

Filters